Intuitive Surgical, Inc.
In this report, Intuitive Surgical, Intuitive, the Company, we, us, and our refer to Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries. Product and brand names and logos, including Intuitive, da Vinci, and Ion, are trademarks or registered trademarks of Intuitive Surgical, Inc. or one of its subsidiaries or of their respective owners.
$426.70
-$1.16 (-0.27%)
EOD Oct 16, 2026
29.27% operating margin is above average. ROIC at 14.52%.
Revenue grew 20.5%, still solid.
At 49x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
49.0x earnings, 46.8x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$11.03B
▲ +20.5% YoY
Net Income (TTM)
$3.14B
▲ +23.0% YoY
Op. Margin
31.28%
▲ +1.1pp YoY
ROIC
15.89%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$3.22B
▲ +91.0% YoY
Op. Cash Flow (TTM)
$3.71B
▲ +25.5% YoY
Net Debt
-$5.22B
Net Cash Position
Cash & Equiv.
$5.22B
5Y CAGR: +18.2%
5Y CAGR: +16.9%
Continue Research
SourceComputed from the 10-Q filed 16 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 22 Jul 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Intuitive Surgical (ISRG) overvalued?
At a P/E of 49.0 and a price-to-free-cash-flow of 46.8, Intuitive Surgical (ISRG) trades above a two-stage DCF intrinsic value of about $317.13 per share, so at $426.70 the stock looks overvalued (25.7% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Intuitive Surgical scores 81/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Intuitive Surgical's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $317.13 per share for ISRG, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $237.85. At today's $426.70, that puts the stock about 25.7% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Intuitive Surgical a high-quality business?+
Intuitive Surgical scores 81 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 31.3% operating margin and a 15.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Intuitive Surgical a good stock to buy right now?+
That depends on valuation and quality together, not either alone. ISRG currently trades above its estimated intrinsic value and scores 81/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.